RxDoctor Payments Data

Amanda Konieczny

Family · Latham, NYNPI 1225600505

Payments from drug & device makers

$3,312in general payments, 2019–2025

Across 154 payments — averaging $21.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$764
  • Novo Nordisk$397
  • GSK$346
  • AstraZeneca$331
  • Lilly USA, LLC$258
  • Boehringer Ingelheim$225
  • plus $990 from 22 others

What the payments were for

  • Food & beverage$3,312100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,312 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$50,224
Medicare patients
235
Services billed
1,263

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$38,524
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$27,420
JardianceEmpagliflozin18$23,466
TradjentaLinagliptin18$13,199
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,425
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,369
Levothyroxine Sodium193$2,850
Omeprazole144$2,209
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,119
Albuterol Sulfate HfaAlbuterol Sulfate71$1,883
Atorvastatin Calcium169$1,714
Losartan Potassium143$1,525
Boostrix TdapDiphth,pertuss(Acell),tet Vac20$1,474
Rosuvastatin Calcium116$1,409
Duloxetine Hcl45$988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$397$38,52439 claims
Boehringer IngelheimJardiance, Tradjenta$225$36,66436 claims
GSKTrelegy Ellipta$346$27,42043 claims
AstraZenecaBreztri Aerosphere$331$12,42520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Latham

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →